ATEC prelim FY2025 rev ~$764M (+25%), FY2026 outlook $890M; acquires OsteoAdapt distribution rights

Alphatec Holdings, Inc.

2025-FY EPS reported -$0.96 revenue$764,155,000

Preliminary FY2025 total revenue ~$764M (25% growth); surgical revenue grew 26% with volume up 24%.
FY2025 adjusted EBITDA reaffirmed at $91M; cash balance ~$161M; Q4 free cash flow expected $6-8M.
FY2026 outlook: total revenue $890M (17% growth), adjusted EBITDA ~$130M, positive free cash flow ~$20M.
Acquired exclusive U.S. distribution rights for Theradaptive's OsteoAdapt (rhBMP-2 biologic, Phase II for spinal fusion).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.